Dissecting mechanisms of fecal microbiota transplantation efficacy in disease
Copyright © 2023 Elsevier Ltd. All rights reserved..
Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent Clostridioides difficile infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term 'dysbiosis' has been used to describe microbial imbalances in relation to disease, but this traditional definition fails to consider the complex cross-feeding networks that define the stability of the microbiome. Emerging research transitions toward the targeted restoration of microbial functional networks in treating different diseases. In this review, we explore potential mechanisms responsible for the efficacy of FMT and future therapeutic applications, while revisiting definitions of 'dysbiosis' in favor of functional network restoration in rCDI, inflammatory bowel diseases (IBDs), metabolic diseases, and cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Trends in molecular medicine - 30(2024), 3 vom: 01. März, Seite 209-222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andary, Catherine M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioenergetics |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.molmed.2023.12.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366859552 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366859552 | ||
| 003 | DE-627 | ||
| 005 | 20240318234030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molmed.2023.12.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM366859552 | ||
| 035 | |a (NLM)38195358 | ||
| 035 | |a (PII)S1471-4914(23)00284-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andary, Catherine M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dissecting mechanisms of fecal microbiota transplantation efficacy in disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent Clostridioides difficile infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term 'dysbiosis' has been used to describe microbial imbalances in relation to disease, but this traditional definition fails to consider the complex cross-feeding networks that define the stability of the microbiome. Emerging research transitions toward the targeted restoration of microbial functional networks in treating different diseases. In this review, we explore potential mechanisms responsible for the efficacy of FMT and future therapeutic applications, while revisiting definitions of 'dysbiosis' in favor of functional network restoration in rCDI, inflammatory bowel diseases (IBDs), metabolic diseases, and cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bioenergetics | |
| 650 | 4 | |a dysbiosis | |
| 650 | 4 | |a fecal microbiota transplantation | |
| 650 | 4 | |a gut microbiota | |
| 700 | 1 | |a Al, Kait F |e verfasserin |4 aut | |
| 700 | 1 | |a Chmiel, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbons, Shaeley |e verfasserin |4 aut | |
| 700 | 1 | |a Daisley, Brendan A |e verfasserin |4 aut | |
| 700 | 1 | |a Parvathy, Seema Nair |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki Vareki, Saman |e verfasserin |4 aut | |
| 700 | 1 | |a Bowdish, Dawn M E |e verfasserin |4 aut | |
| 700 | 1 | |a Silverman, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, Jeremy P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in molecular medicine |d 2001 |g 30(2024), 3 vom: 01. März, Seite 209-222 |w (DE-627)NLM111960800 |x 1471-499X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:209-222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molmed.2023.12.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 01 |c 03 |h 209-222 | ||